 |
|
Personalized immunotherapy to fight HIV/AIDS
August 18, 2008For a long time, the main obstacle to creating an AIDS vaccine has been the high genetic variability of the HIV virus. Dr. Jean-Pierre Routy and his team from the Research Institute of the McGill University Health Centre (MUHC), in collaboration with Dr. Rafick Sékaly from the Université de Montréal, have overcome this difficulty by designing a personalized immunotherapy for HIV-infected patients. The team's findings were presented on August 5 at the XVII International AIDS Conference in Mexico City.
"Our approach is unique in the world: no one else has yet developed customized immunotherapy using the virus from individual patients," said Dr. Routy. "This experimental technique remains long and costly for the moment, but we're hoping it will hold the promise of a completely innovative and widely available treatment in the future."
This immunotherapy is based on the properties of dendritic cells, whose role is to present specific proteins from infectious organisms at their surface, thereby alerting the rest of the immune system. In collaboration with Argos Therapeutics, the researchers designed a study in which the dendritic cells of nine study patients were multiplied in vitro and then treated with the RNA (ribonucleic acid) from the virus that had infected each patient. A virus sample was taken before the administration of any antiretroviral treatment.
The surfaces of these manipulated dendritic cells present an increased number of HIV proteins, which allows them to stimulate the cytotoxic response of a certain type of immune cell called CD8+ lymphocytes. After receiving multiple subcutaneous injections of these dendritic cells, eight of the nine patients involved experienced a significant increase in CD8+ lymphocyte activity.
"At this stage, we have shown that the technique doesn't cause side effects or an undesirable auto-immune response," said Dr. Routy. "Health Canada has approved a multicentre clinical trial across the country that will let us further assess the technique's effectiveness at controlling HIV reproduction. We're hoping that the FDA in the United States will also give us the go-ahead soon so that our pharmaceutical partner, Argos Therapeutics, can begin testing in the United States."
While more research needs to be done, this new target may lead to an innovative therapeutic approach to fight the AIDS pandemic.
McGill University Health Centre
The surfaces of these manipulated dendritic cells present an increased number of HIV proteins, which allows them to stimulate the cytotoxic response of a certain type of immune cell called CD8+ lymphocytes. After receiving multiple subcutaneous injections of these dendritic cells, eight of the nine patients involved experienced a significant increase in CD8+ lymphocyte activity.
"At this stage, we have shown that the technique doesn't cause side effects or an undesirable auto-immune response," said Dr. Routy. "Health Canada has approved a multicentre clinical trial across the country that will let us further assess the technique's effectiveness at controlling HIV reproduction. We're hoping that the FDA in the United States will also give us the go-ahead soon so that our pharmaceutical partner, Argos Therapeutics, can begin testing in the United States."
While more research needs to be done, this new target may lead to an innovative therapeutic approach to fight the AIDS pandemic.
McGill University Health Centre
Immunotherapy Current Events and Immunotherapy News RSSImmune system activated in schizophrenia
Researchers at the Swedish medical university Karolinska Institutet have discovered that patients with recent-onset schizophrenia have higher levels of inflammatory substances in their brains. Their findings offer hope of being able to treat schizophrenia with drugs that affect the immune system.
Hundreds of genes distinguish patients likely to survive advanced melanoma
Although the chances of surviving advanced melanoma aren't very good with current therapies, some patients can live for years with cancer that has spread beyond the skin to other organs.
Immunotherapy demonstrates long-term success in treating lymphoma
Targeted immunotherapy has been an attractive new therapeutic area for a number of cancers because it has the potential to destroy tumor cells without damaging surrounding normal tissue. New study results demonstrate high success rates using specialized white blood cells to prevent or treat lymphoma associated with the Epstein-Barr virus (EBV-lymphoma) in patients who have received a hematopoietic stem cell transplant (HSCT).
Alzheimer's lesions found in the retina
The eyes may be the windows to the soul, but new research indicates they also may mirror a brain ravaged by Alzheimer's disease.
Elderly immune system needs a boost
Elderly cancer patients need a combination of treatments tailor-made to their specific needs to successfully combat the disease.
Oleocanthal may help prevent, treat Alzheimer's
Oleocanthal, a naturally-occurring compound found in extra-virgin olive oil, alters the structure of neurotoxic proteins believed to contribute to the debilitating effects of Alzheimer's disease. This structural change impedes the proteins' ability to damage brain nerve cells.
University Hospitals Case Medical Center to test gammaglobulin treatment for Alzheimer's disease
Researchers from the Memory and Cognition Center at University Hospitals Case Medical Center will begin testing an intriguing new approach to slowing down the progression of Alzheimer's Disease (AD) using Intravenous Immune Globulin (IGIV), also known as gammaglobulin.
Mounting a multi-layered attack on fungal infections
Unravelling a microbe's multilayer defence mechanisms could lead to effective new treatments for potentially lethal fungal infections in cancer patients and others whose natural immunity is weakened.
Phase 3 Alzheimer's drug increases toxic beta amyloid in the brain -- but still provides benefits
New insights into how a Phase III Alzheimer's drug might work were among the advances in potential therapies targeting two abnormal brain proteins - beta amyloid and phosphorylated tau - that were reported today at the Alzheimer's Association 2009 International Conference on Alzheimer's Disease (ICAD 2009) in Vienna.
Researchers testing virus-gene therapy combination against melanoma
Researchers at the Moores UCSD Cancer Center are injecting a modified herpes virus into melanoma tumors, hoping to kill the cancer cells while also bolstering the body's immune defenses against the disease.
More Immunotherapy Current Events and Immunotherapy News Articles
 |
Cancer Immunotherapy: Immune Suppression and Tumor Growth by George C. Prendergast (Editor), Elizabeth M. Jaffee (Editor) There has been major growth in understanding immune suppression mechanisms and its relationship to cancer progression and therapy. This book highlights emerging new principles of immune suppression that drive cancer and it offers radically new ideas about how therapy can be improved by attacking these principles. Following work that firmly establishes immune escape as an essential trait of cancer, recent studies have now defined specific mechanisms of tumoral immune suppression. It also demonstrates how attacking tumors with molecular targeted therapeutics or traditional chemotherapeutic drugs can produce potent anti-tumor effects in preclinical models. This book provides basic, translational, and clinical cancer researchers an indispensable overview of immune escape as a critical trait... |
 |
Recombinant Antibodies for Immunotherapy by Melvyn Little PhD (Editor) Recombinant Antibodies for Immunotherapy provides a comprehensive overview of the field of monoclonal antibodies (mAbs), a market that has grown tremendously in recent years. Twenty-five articles by experienced and innovative authors cover the isolation of specific human mAbs, humanization, immunogenicity, technologies for improving efficacy, "arming" mAbs, novel alternative Ab constructs, increasing half-lives, alternative concepts employing non-immunoglobulin scaffolds, novel therapeutic approaches, a market analysis of therapeutic mAbs, and future developments in the field. The concepts and technologies are illustrated by examples of recombinant antibodies being used in the clinic or in development. This book will appeal to both newcomers and experienced scientists in the field,... |
 |
Using the Immune System to Treat Cancer |
 |
Allergens and Allergen Immunotherapy, Fourth Edition (Clinical Allergy and Immunology) by Richard F. Lockey (Editor), Dennis K. Ledford (Editor) Modernized and updated, Allergens and Allergen Immunotherapy, Fourth Edition discusses all major areas of allergens and immunotherapies: pollens animal/insect fungi food the manufacture and standardization of allergen vaccines the administration of vaccines the avoidance and treatment of adverse effects Compiling the research of an influential team of investigators and scientists, Allergens and Allergen Immunotherapy is filled with quick reference charts, tables and indexes. Allergists, immunologists, and otolaryngologists will find this new streamlined fourth edition a great practical reference for on-the-go diagnosis, treatment, and management of allergies. NEW TO THE FOURTH EDITION: new focus on the most... |
 |
Antiviral Agents, Vaccines and Immunotherapies (Infectious Disease and Therapy) by Stephen Tyring (Editor) Unlike any other source on the subject, Antiviral Agents, Vaccines, and Immunotherapies analyzes the benefits and limitations of every available drug, vaccine, and immunotherapy utilized in the prevention and control of viral diseases. This reference provides in-depth reviews of more than 50 drugs and antiviral agents for HIV, human herpesviruses, human papillomaviruses (HPV), influenza, respiratory syncytial virus, hepatitis B, and analyzes their mechanisms of action, dosage, side effects, and drug resistance. The book also provides an overview of the use of immunoglobulins and monoclonal antibodies for antiviral use and supplies extensive references, tables, and figures throughout the text. |
 |
Carbohydrate-Based Vaccines and Immunotherapies (Wiley Series in Drug Discovery and Development) by Zhongwu Guo (Author), Geert-Jan Boons (Author) The fundamental science and the latest developments in carbohydrate-based vaccines The relatively new field of glycoimmunology has emerged from the marriage of glycobiology and immunology, in recognition of the important role carbohydrates play as antigenic determinants. Carbohydrate-Based Vaccines and Immunotherapies comprehensively reviews the state of this exciting field, offering a single source for both the fundamental science and the latest developments. With contributions by leading experts, this resource covers the design, synthesis, evaluation, and applications of various carbohydrate-based vaccines, including polysaccharides, neoglycoproteins, and neoglycolipids. The text approaches vaccine design from a chemical and molecular focus, staying in line with... |
 |
Cancer Vaccines and Immunotherapy (Cambridge Cancer Series) by Peter L. Stern (Editor), Peter C. L. Beverley (Editor), Miles Carroll (Editor) Rapid progress in the definition of tumor antigens, and improved immunization methods, bring effective cancer vaccines within reach. In this wide-ranging survey, leading clinicians and scientists review therapeutic cancer vaccine strategies against a variety of diseases and molecular targets. Intended for an interdisciplinary readership, their contributions cover the rationale, development, and implementation of vaccines in human cancer treatment, with specific reference to cancer of the cervix, breast, colon, bladder, and prostate, and to melanoma and lymphoma. They review target identification, delivery vectors and clinical trial design. The book begins and ends with lucid overviews from the editors, that discuss the most recent developments. |
 |
The Low Dose Immunotherapy Handbook: Recipes and Lifestlye Advice for Patients on LDA and EPD Treatment by Nicolette, M Dumke (Author) The Low Dose Immunotherapy Handbook: Recipes and Lifestyle Tips for Patients on LDA and EPD Treatment gives 80 recipes for patients on low dose immunotherapy treatment for their food allergies. These recipes are for the basic shot time (EPD) diet and the very mixed diet, and include baked goods, main dishes, and side dishes as well as allowable snacks, desserts and treats that make these diets more livable. It also includes organizational information to help you get ready for your shots and sources of special foods and products that low dose immunotherapy patients need. |
|
PEPTIDE IMMUNOTHERAPY - COLOSTRUM, A PHYSICIAN'S REFERENCE GUIDE by Andrew M., PhD Keech (Author) | |
 |
Immune Regulation and Immunotherapy in Autoimmune Disease by Jingwu Zhang (Editor) This volume will review the most recent advances in the understanding of cellular and molecular mechanisms for immune responses and immune regulation. Chapters in the first portion of this book will discuss the theoretical basis for current immunotherapies for autoimmune diseases. The second portion of the book will provide an updated review on the research behind the clinical trials/immunotherapies (e.g. T-cell vaccination, antibody therapy, etc.) in the areas of autoimmune diseases by the principal investigators of these studies. These chapters will discuss clinical and basic research as well as immunological data in the context of cellular and molecular mechanisms of the therapies. The book will finish with chapters by leaders in the field who will provide expert views on challenges... |
| © 2009 BrightSurf.com |